Rate Video

ASCO 2022 | Key takeaways in leukemia at ASCO 2022

Eunice Wang • 3 Jun 2022

ASCO 2022

Acute Myeloid Leukemia Leukemia

Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, provides an overview of key updates in leukemia presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including novel approaches using bispecific antibodies, as well as targeted approaches in acute myeloid leukemia (AML). This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

IDH inhibitors for AML and MDS

Eunice Wang • 1 Jun 2018

Key targets and the future of immunotherapy in AML

Eunice Wang • 27 May 2021

Efficacy of PARP inhibitors in the treatment of AML

Eunice Wang • 13 Dec 2021

Update on a Phase I/II study of ziftomenib in patients with R/R AML

Eunice Wang • 12 Dec 2022

Related Videos

Key challenges of using the intestinal microbiome as a biomarker

CAR T-cell therapy: the importance of LTFU

The future of AML therapy

Andreas Burchert

Treating pediatric patients with hematological malignancies

Claudia Rössig